Becton Dickinson/$BDX

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX

About Becton Dickinson

Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.

Ticker

$BDX

Primary listing

NYSE

Industry

Health Care Equipment & Supplies

Employees

74,000

ISIN

US0758871091
Website

Becton Dickinson Metrics

BasicAdvanced
$51B
34.34
$5.16
0.38
$4.07
2.35%

What the Analysts think about Becton Dickinson

Analyst ratings (Buy, Hold, Sell) for Becton Dickinson stock.

Bulls say / Bears say

Becton Dickinson's acquisition of Edwards Lifesciences' critical care products unit for $4.2 billion is expected to enhance its product portfolio and drive revenue growth. (reuters.com)
Analysts have set a 12-month stock price forecast of $231.5 for BDX, indicating a potential upside of 36.20% from the latest price. (stockanalysis.com)
BDX has been increasing its dividend for 53 consecutive years, demonstrating a strong commitment to returning value to shareholders. (marketbeat.com)
BDX settled charges with the SEC over misleading investors about risks associated with its Alaris infusion pump, agreeing to pay a $175 million civil penalty. (reuters.com)
The company canceled a €206 million investment in a syringe manufacturing plant in Zaragoza, Spain, leading to layoffs and potential reputational damage. (cadenaser.com)
BDX's debt-to-equity ratio decreased to 0.35 in Q4 2024 from 0.75 in Q3 2024, indicating reduced reliance on debt financing, but the company's return on equity also declined to 0.01, suggesting lower profitability. (siriusinvestors.com)
Data summarised monthly by Lightyear AI. Last updated on 2 Jul 2025.

Becton Dickinson Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Becton Dickinson Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BDX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs